Author:
Kroidl Arne,Ello Frederic,Mgaya Jimson,Lennemann Tessa,Moh Raoul,Maganga Lucas,Eholie Serge,Pruvost Alain,Saathoff Elmar,Girard Pierre-Marie,Zuhse Ralph,von Massow Friedrich,Anglaret Xavier,Hoelscher Michael,Danel Christine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference16 articles.
1. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial;Richman;N Engl J Med,1987
2. Catabolism of 3’-azido-3’-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3’-amino-3’-deoxythymidine, a highly toxic catabolite for human bone marrow cells;Cretton;Mol Pharmacol,1991
3. Differences in resistance mutations among HIV-1 nonsubtype B infections: a systematic review of evidence (1996-2008);Martinez-Cajas;J Int AIDS Soc,2009
4. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B;Montes;J Acquir Immune Defic Syndr,2004
5. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d’Ivoire;Moh;Antivir Ther,2005